Company Description
Kindly MD, Inc., a healthcare and healthcare data company, provides direct health care services to patients integrating prescription medicine and behavioral health services.
The company offers specialty outpatient clinical services based on a subscription and fee-for-service basis to augment traditional healthcare.
It provides evaluation and management services, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support, overdose education, peer support, limited urgent care, preventative medicine, travel, and hormone therapy; and data collection and research, and online and email campaign marketing services.
The company also builds a portfolio of bitcoin-native companies. Kindly MD, Inc. was formerly known as Utah Therapeutic Health Center, LLC and changed its name to Kindly MD, Inc. in March 2022.
The company was incorporated in 2019 and is based in Salt Lake City, Utah.
| Country | United States |
| Founded | 2019 |
| IPO Date | May 31, 2024 |
| Industry | Medical Care Facilities |
| Sector | Healthcare |
| Employees | 61 |
| CEO | David Bailey |
Contact Details
Address: 5097 South 900 East, Suite 100 Salt Lake City, Utah 84117 United States | |
| Phone | 385 388 8220 |
| Website | kindlymd.com |
Stock Details
| Ticker Symbol | NAKA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001946573 |
| ISIN Number | US49457M1062 |
| Employer ID | 84-3829824 |
| SIC Code | 6199 |
Key Executives
| Name | Position |
|---|---|
| David Forrest Bailey | Chairman and Chief Executive Officer |
| Jared E. Barrera M.B.A. | Chief Financial Officer |
| Timothy Pickett | Chief Medical Officer and Director |
| Amanda Fabiano | Chief Operating Officer |
| Tyler Matthew Evans | Chief Investment Officer |
| Andrew Creighton | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | POS AM | Post-Effective amendments for registration statement |
| Nov 21, 2025 | 424B3 | Prospectus |
| Nov 19, 2025 | 8-K | Current Report |
| Nov 19, 2025 | 10-Q | Quarterly Report |
| Nov 14, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 3, 2025 | ARS | Filing |
| Nov 3, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 3, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 3, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 23, 2025 | PRE 14A | Other preliminary proxy statements |